{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T03:09:32Z","timestamp":1771384172665,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.acuro.2013.06.006","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T02:00:37Z","timestamp":1386381637000},"page":"192-199","source":"Crossref","is-referenced-by-count":6,"title":["Implicaci\u00f3n de las mol\u00e9culas HLA de clase I en el escape inmunitario de tumores urol\u00f3gicos"],"prefix":"10.1016","volume":"38","author":[{"given":"R.","family":"Carretero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gil-Julio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"V\u00e1zquez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Casti\u00f1eiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"C\u00f3zar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2013.06.006_bib0005","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.0405730101","article-title":"Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes","volume":"101","author":"Rosenberg","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.acuro.2013.06.006_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.20499","article-title":"Coordinated downregulation of the antigen presentation machinery and HLA class I\/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer","volume":"113","author":"Romero","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acuro.2013.06.006_bib0015","first-page":"429","article-title":"Tumor immunity in mice, induced with lyophilized tissue, as influenced by tumor strain, host strain, source of tissue, and dosage","volume":"8","author":"Snell","year":"1948","journal-title":"Cancer Res"},{"key":"10.1016\/j.acuro.2013.06.006_bib0020","first-page":"244","article-title":"Identity of leukocytic antigens detectable from immune iso-leuko-agglutinins in monozygotic twins","volume":"151","author":"Dausset","year":"1957","journal-title":"C R Seances Soc Biol Fil"},{"key":"10.1016\/j.acuro.2013.06.006_bib0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.70.5.1603","article-title":"Papain-solubilized HLA antigens from cultured human lymphocytes contain two peptide fragments","volume":"70","author":"Cresswell","year":"1973","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.acuro.2013.06.006_bib0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev.iy.07.040189.003125","article-title":"Antigen recognition by class I-restricted T lymphocytes","volume":"7","author":"Townsend","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0035","first-page":"273","article-title":"Ueberden jetzigen stand der karzinomforshung","volume":"5","author":"Ehrlich","year":"1909","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.acuro.2013.06.006_bib0040","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"Br Med J"},{"key":"10.1016\/j.acuro.2013.06.006_bib0045","series-title":"Celular and humoral aspects of the hypersensitive states","author":"Thomas","year":"1959"},{"key":"10.1016\/j.acuro.2013.06.006_bib0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0198-8859(99)00150-0","article-title":"HLA class I expression on human cancer cells Implications for effective immunotherapy","volume":"61","author":"Tait","year":"2000","journal-title":"Hum Immunol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.acuro.2013.06.006_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7182\/prtr.14.3.t7r41052414t1u20","article-title":"Posttransplant malignancy","volume":"14","author":"Trofe","year":"2004","journal-title":"Prog Transplant"},{"key":"10.1016\/j.acuro.2013.06.006_bib0065","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"Van der Bruggen","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.acuro.2013.06.006_bib0070","doi-asserted-by":"crossref","first-page":"14137","DOI":"10.1371\/journal.pone.0014137","article-title":"Screening of human tumor antigens for CD4T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries","volume":"5","author":"Olsen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.acuro.2013.06.006_bib0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1034\/j.1399-0039.2003.00104.x","article-title":"HLA class I expression in bladder carcinomas","volume":"62","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.acuro.2013.06.006_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00251-004-0692-z","article-title":"Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21","volume":"56","author":"Maleno","year":"2004","journal-title":"Immunogenetics"},{"key":"10.1016\/j.acuro.2013.06.006_bib0085","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00262-009-0701-z","article-title":"HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank","volume":"58","author":"Mendez","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.acuro.2013.06.006_bib0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.280.5361.248","article-title":"Viral strategies of immune evasion","volume":"280","author":"Ploegh","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.acuro.2013.06.006_bib0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0065-230X(01)83005-0","article-title":"MHC antigens and tumor escape from immune surveillance","volume":"83","author":"Garrido","year":"2001","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.acuro.2013.06.006_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2370.2003.00384.x","article-title":"Tumour immunology, vaccination and escape strategies","volume":"30","author":"Garc\u00eda-Lora","year":"2003","journal-title":"Eur J Immunogenet"},{"key":"10.1016\/j.acuro.2013.06.006_bib0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ijc.25270","article-title":"Hard and soft lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy","volume":"127","author":"Garrido","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acuro.2013.06.006_bib0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.acuro.2011.12.001","article-title":"Gu\u00eda cl\u00ednica del carcinoma urotelial de vejiga no m\u00fasculo-invasivo de la Asociaci\u00f3n Europea de Urolog\u00eda. Actualizaci\u00f3n de 2011","volume":"36","author":"Babjuk","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.06.006_bib0115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.humimm.2012.03.006","article-title":"Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer","volume":"73","author":"Guirado","year":"2012","journal-title":"Hum Immunol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00262-009-0765-9","article-title":"Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas","volume":"59","author":"Cathro","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.acuro.2013.06.006_bib0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00251-006-0111-8","article-title":"LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas","volume":"58","author":"Maleno","year":"2006","journal-title":"Immunogenetics"},{"key":"10.1016\/j.acuro.2013.06.006_bib0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1699-0463.1993.tb00142.x","article-title":"Expression of beta 2-microglobulin by premalignant epithelium","volume":"101","author":"Petersen","year":"1993","journal-title":"APMIS"},{"key":"10.1016\/j.acuro.2013.06.006_bib0135","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/1097-0142(19911215)68:12<2591::AID-CNCR2820681212>3.0.CO;2-L","article-title":"Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival","volume":"68","author":"Levin","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2013.06.006_bib0140","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/1078-0432.CCR-06-0595","article-title":"Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer","volume":"12","author":"Kitamura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuro.2013.06.006_bib0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","article-title":"Loss of HLA class I expression in prostate cancer: implications for immunotherapy","volume":"46","author":"Blades","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2013.06.006_bib0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.acuro.2011.10.013","article-title":"Mortalidad por c\u00e1ncer de pr\u00f3stata en el rama espa\u00f1ola del European Randomized Study of Screening for Prostate Cancer (ERSPC). Resultados tras 15 a\u00f1os de seguimiento","volume":"36","author":"Lujan","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.06.006_bib0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.juro.2007.03.109","article-title":"Down-Regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition","volume":"178","author":"Kitamura","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s002510100371","article-title":"A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line","volume":"53","author":"Jim\u00e9nez","year":"2001","journal-title":"Immunogenetics"},{"key":"10.1016\/j.acuro.2013.06.006_bib0165","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00262-009-0769-5","article-title":"Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer","volume":"59","author":"Seliger","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.acuro.2013.06.006_bib0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.acuro.2011.09.003","article-title":"Incidencia, prevalencia y mortalidad de c\u00e1ncer renal en Espa\u00f1a: estimaciones y proyecciones para el per\u00edodo 1998-2022","volume":"36","author":"Souza","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2013.06.006_bib0180","article-title":"Metastasis of renal cell carcinoma to the buccal mucosa 19 years after radical nephrectomy","volume":"823042","author":"Gil-Julio","year":"2012","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.acuro.2013.06.006_bib0185","first-page":"638","article-title":"Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy","volume":"15","author":"Hanak","year":"2009","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.acuro.2013.06.006_bib0190","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.juro.2006.11.082","article-title":"Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma","volume":"177","author":"Kitamura","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-0039.2009.01409.x","article-title":"Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue","volume":"75","author":"S\u00e1enz-L\u00f3pez","year":"2010","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.acuro.2013.06.006_bib0200","first-page":"505","article-title":"HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation","volume":"18","author":"Brasanac","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.acuro.2013.06.006_bib0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1399-0039.2006.00673.x","article-title":"Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma","volume":"68","author":"Romero","year":"2006","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.acuro.2013.06.006_bib0210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/qjmed\/hcn050","article-title":"Advances in tumour immunotherapy","volume":"101","author":"King","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.acuro.2013.06.006_bib0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2013.06.006_bib0220","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.urology.2005.11.052","article-title":"Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy","volume":"67","author":"Kitamura","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2013.06.006_bib0225","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of bacille Calmette-Gu\u00e9rin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2013.06.006_bib0230","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.25733","article-title":"BCG immunotherapy of bladder cancer induces selection of HLA class I-deficient tumor cells","volume":"129","author":"Carretero","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.acuro.2013.06.006_bib0235","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/annonc\/mdq544","article-title":"Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination","volume":"21","author":"Yasukawa","year":"2010","journal-title":"Ann Oncol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480613002817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480613002817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:41:27Z","timestamp":1716266487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480613002817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0210480613002817"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2013.06.006","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}